NEW YORK, September 8, 2009 The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors six days per week or more rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices including experiencing fewer low blood sugar emergencies.
The findings of two studies from the major multi-center trial funded by the Juvenile Diabetes Research Foundation were published online by the journal Diabetes Care (available at http://care.diabetesjournals.org/papbyrecent.shtml). The first showed that regular use of CGM devices is the principal factor in achieving better diabetes control, rather than the age of people using the monitors, or other demographic, clinical, or psychosocial factors. The second showed that people using CGM to help manage their disease were able to sustain good diabetes control; and just as important, that continued strong control came while actually lowering the incidence of hypoglycemia dangerous low-blood-sugar incidents that can occur with tightly managed type1 diabetes.
"Based on these results and previous JDRF CGM trials published over the past 12 months, we know that these devices can help people get in control of their diabetes, help people already managing their disease maintain good control, and help people stay in control over an extended period of time, while lowering their risk for hypoglycemia," said Dr. William V. Tamborlane, of Yale University, a co-chair of the JDRF funded study.
Research has shown that good blood sugar control is a key factor in reducing the risk of the devastating long-term complications of the disease, such as blindness and kidney disease but that the fear of low blood
|Contact: Joana Casas|
Juvenile Diabetes Research Foundation International